Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of Fluvirin influenza vaccine in healthy adults
2013-000601-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza, sponsored by Novartis. Primary endpoint: Immunogenicity Endpoints. Started Mar 2013; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-000601-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000601-23.